

Vitamin D, and Kidney Disease

Hyung Soo Kim, M.D.
Woogyung Chung, M.D.
Sejoong Kim, M.D.

Department of Internal Medicine, Gachon University of Medicine and Science, Incheon, Korea

Received: June 9, 2011

Accepted: June 14, 2011

Corresponding author: Sejoong Kim, M.D.
Department of Internal Medicine, Gachon University Gil Hospital, 1198 Guwol-dong, Namdong-gu, Incheon, 405-760, Korea
Tel: +82-32-460-8305, Fax: +82-32-460-3431
E-mail: imsejoong@daum.net

Mineral metabolism abnormalities, such as low 1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}$) and elevated parathyroid hormone (PTH), are common at even higher glomerular filtration rate than previously described. Levels of 25-hydroxyvitamin D ($25(\text{OH})\text{D}$) show an inverse correlation with those of intact PTH and phosphorus. Studies of the general population found much higher all-cause and cardiovascular (CV) mortality for patients with lower levels of vitamin D; this finding suggests that low $25(\text{OH})\text{D}$ level is a risk factor and predictive of CV events in patients without chronic kidney disease (CKD). $25(\text{OH})\text{D}/1,25(\text{OH})_2\text{D}$ becomes deficient with progression of CKD. Additionally, studies of dialysis patients have found an association of vitamin D deficiency with increased mortality. Restoration of the physiology of vitamin D receptor activation should be essential therapy for CKD patients.

Key Words: renal insufficiency, chronic; vitamin D; deficiency

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Vitamin D is known to be essential for bone metabolism. The number of peer-reviewed publications with the term 'vitamin D' in their title or abstract has increased greatly since the early 2000s¹⁾. PubMed currently lists over 25,000 publications from 1950 to the present. In the 1960s, fewer than 100 papers on 'vitamin D' were published per year; however, in 2010, this rate of publication reached approximately 2,500 papers per year. This expansion of research over recent decades has resulted in a dramatic increase in our understanding of additional biological actions of vitamin D on various systems including pancreas β -cell function, immune, cardiovascular, muscle, and brain systems, and control of the cell cycle. An interesting relationship exists between mortality in ischemic heart disease and geographic latitude in European countries²⁾, which shows an increase in the mortality of heart

diseases with increase in latitude. Additionally, serum 25-hydroxyvitamin D ($25(\text{OH})\text{D}$) levels have been shown to be higher in healthy subjects at lower latitudes²⁾.

Vitamin D, hyperparathyroidism, and vascular calcification

Vitamin D plays a well-known role in the regulation of phosphate homeostasis. Phosphate is absorbed from the diet in the gut, stored in the skeleton, and excreted by the kidneys; 1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}$) stimulates absorption of phosphate from the diet³⁾. Fibroblast growth factor (FGF)-23 increases renal phosphate clearance, suppresses synthesis of $1,25(\text{OH})_2\text{D}$, and may decrease parathyroid hormone (PTH). PTH increases renal phosphate clearance and stimulates synthesis of $1,25(\text{OH})_2\text{D}$ ⁴⁾. In chronic kidney disease (CKD) patients, ionizing calcium (iCa) is decreased secondary to phosphate

retention and decrease in $1,25(\text{OH})_2\text{D}$. Phosphate retention increases FGF-23, which, in conjunction with its cofactor, Klotho protein, decreases the activity of 1α -hydroxylase and increases 24α -hydroxylase, thus decreasing the levels of circulating $1,25(\text{OH})_2\text{D}$. Additionally, phosphate retention results in an increase in posttranscriptional synthesis of PTH. Decreases in the vitamin D receptor (VDR), calcium sensor receptor, and Klotho–FGFR1 receptor complex in the parathyroid gland aggravate the development of the secondary hyperparathyroidism in CKD patients⁴⁾.

Apart from hyperparathyroidism, calcium and phosphate imbalance and vitamin D deficiency also contribute to vascular calcification. A cross-sectional study by Gracia-Canton et al. has reported an independent negative association between serum levels of $25(\text{OH})\text{D}$ and vascular calcification in 210 patients with stage 4 and 5 CKD⁵⁾. Plain X-ray images of pelvis, hands, and lateral lumbar spines from all subjects were studied for calculation of semi-quantitative vascular calcification scores, as described by Adragao⁶⁾ and Kauppila⁷⁾. Adragao scores revealed only 47 patients (22.4%) without vascular calcification and 120 patients (57.1%) with scores higher than 3⁵⁾. Kauppila scores revealed only 29 patients (13.8%) without aortic calcifications and 114 patients (54.3%) with scores higher than 7⁵⁾. Higher vascular calcification scores were related




Fig. 1. Prevalence of Vitamin D Deficiency and Vascular Calcification in Stage 4 and 5 CKD. CKD, chronic kidney disease; $25(\text{OH})\text{D}$, 25-hydroxyvitamin D; white box, Adragao score⁶⁾; gray box, Kauppila score⁷⁾.

*Data from the study of Garcia-Canton C et al. Ref. 5.

to older age, diabetes, history of cardiovascular disease (CVD), and lower levels of $25(\text{OH})\text{D}$ ⁵⁾. Only one-fifth of patients had adequate levels of $25(\text{OH})\text{D}$, whereas a half had vitamin D insufficiency, and a quarter had vitamin deficiency (Fig. 1)⁵⁾.

Vitamin D and vitamin D receptor

Vitamin D is a multifunctional hormone that can affect many essential biological functions, ranging from immune regulation to mineral ion metabolism. Calcitriol or $1,25(\text{OH})_2\text{D}$ is the active form of vitamin D, formed by dual hydroxylation in the liver and kidney. Figure 2 shows a simplified diagram of the different stages of vitamin D synthesis⁸⁾. Vitamin D₂ (ergocalciferol), which is absorbed mainly from food, and vitamin D₃ (cholecalciferol), produced in the skin by photolytic cleavage of 7-dehydrocholesterol, is transported to the liver and converted to $25(\text{OH})\text{D}$, the major circulating metabolite of vitamin D. The final activation step, 1-hydroxylation, occurs primarily, but not exclusively, in the kidney, forming $1,25(\text{OH})_2\text{D}$.

Active vitamin D metabolites exert biological activities




Fig. 2. Synthesis of Vitamin D. D2, vitamin D2; D3, vitamin D3; VDR, vitamin D receptor.

*Modified from the study of Razzaque MS. Ref. 8.




Fig. 3. Function of Vitamin D Receptor (VDR) Conformational Ensemble: Genomic or Rapid Responses.

*Modified from the study of Norman AW et al. Ref. 1.

mainly through the VDR¹⁾. VDRs are operational in at least 38 tissues of the body. In these target tissues, VDR functions in the cell nucleus as a transcriptional factor influencing approximately 3% of the human genome, and in the plasma membrane caveolae as a modulator of signal transduction pathways (Fig. 3). The activity of the VDR conformational ensemble (with 2 ligand pockets) can generate either genomic or rapid biological responses. In this model, one shape (6-s-trans) of the conformationally flexible $1\alpha,25(\text{OH})_2\text{D}$ can interact with VDR localized in the cell nucleus to generate genomic responses via regulation of gene transcription, whereas a different shape (6-s-cis) of $1\alpha,25(\text{OH})_2\text{D}$ binds to the second ligand pocket of the VDR associated with caveolae of the plasma membrane to generate rapid responses¹⁾. VDR activation through these pathways has been shown to have wide-ranging effects. Calcitropic functions of $1,25(\text{OH})_2\text{D}$ include physiological regulation of calcium transport and bone mineralization. Synthesis of circulating $1,25(\text{OH})_2\text{D}$, which mediates these calcitropic actions, is tightly regulated. Non-calcitropic actions involve activation of VDRs by locally produced $1,25(\text{OH})_2\text{D}$ in a number of tissues in a paracrine and autocrine fashion⁹⁾. In particular, vitamin D is closely linked to CVD²⁾. Experimental studies have shown that vitamin

D treatment reduces neurohormonal activation, inhibits inflammation, and suppresses ventricular hypertrophy¹⁰⁾.

Vitamin D deficiency in CKD

The recent Workshop Consensus for Vitamin D Nutritional Guidelines estimated that approximately 50% and 60% of the older populations in North America and the rest of the world, respectively, do not have satisfactory vitamin D status¹¹⁾. The consensus further concluded that the situation is similar in younger subjects. Reasons for this remain unclear but are probably related to factors such as urbanization, demographic shifts, decreased outdoor activity, air pollution, global dimming, and decrease in cutaneous production of vitamin D with age. Epidemiological investigations in many countries have shown high prevalence of unsatisfactory vitamin D status (Table 1)¹²⁻¹⁵⁾. In particular, the 2008 Korea National Health and Nutrition Examination Survey (KNHANES) found vitamin D insufficiency in 47.3% of male and 64.5% of female subjects¹⁵⁾.

The outpatient cross-sectional cohort study conducted by Levin et al. has revealed that abnormalities of mineral metabolism occur early in CKD¹⁶⁾. A decrease in

Table 1. Definition and Prevalence of Vitamin D Deficiency in the General Population

Nations	US ¹²⁾	Germany ¹³⁾	New Zealand ¹⁴⁾	Korea ¹⁵⁾
Participants	N = 4,495 (age ≥ 20 yrs)	N = 7,124 (age ≥ 18 yrs)	N = 2,946 (age ≥ 15 yrs)	N = 6,529 (age ≥ 20 yrs)
Definition	25(OH)D ≤ 20 ng/mL	25(OH)D ≤ 20 ng/mL	25(OH)D ≤ 20 ng/mL	25(OH)D ≤ 20 ng/mL
Prevalence	41.6%	57.3%	48%	54.3%
Mean 25(OH)D (ng/mL)	20.1/19.9	18.08/17.88	20.8/18.8	22.36/18.52
Survey	2005-2006	1997-1999	1996-1997	2008

25(OH)D, 25-hydroxyvitamin D.

1,25(OH)₂D levels was above the range of glomerular filtration rate (GFR) values even in the early stage of CKD¹⁶⁾. Similarly, significant inverse correlations were observed among serum phosphate, FGF-23 and PTH levels, and GFR in patients with stage 1 to 3 CKD¹⁷⁾. Hypovitaminosis D is prevalent even in patients with early-stage CKD¹⁸⁾. It is consistent with the previous data that 25(OH)D deficiency worsens with the progression of CKD. Therefore, the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines have recommended annual measurement of 25(OH)D and have also recommended that the level should be maintained at 30 ng/mL or higher in patients with any stage of CKD¹⁹⁾.

Decreased VDR activation and clinical outcomes

Melamed et al. tested the association of low 25(OH)D levels with all-cause, cancer, and CVD mortality in 13,331 nationally representative adults from the Third National Health and Nutrition Examination Survey (NHANES III) linked mortality files²⁰⁾. In this cross-sectional multivariate analysis, increasing age, female sex, non-white race/ethnicity, diabetes, current smoking, and higher body mass index were all independently associated with higher odds of 25(OH)D deficiency, whereas greater physical activity, vitamin D supplementation, and non-winter season showed an inverse association²⁰⁾. In multivariate models, compared with the highest quartile, being in the lowest quartile for 25[OH]D levels (< 17.8 ng/mL) was associated with a 26% increased rate of all-cause mortality (mortality rate ratio, 1.26; 95% CI, 1.08–1.46) and a population attributable risk of 3.1%²⁰⁾. The prospective cohort study by Dobnig et al., which enrolled patients undergoing diagnostic coronary

angiography with normal kidney function showed a similar result with regard to relationships between endogenous 25(OH)D and 1,25(OH)₂D levels and all-cause and cardiovascular mortality²¹⁾. Multivariate-adjusted hazard ratios (HRs) for patients with lower levels of 25(OH)D were two times higher for all-cause mortality and cardiovascular mortality²¹⁾.

A meta-analysis of randomized controlled trials by Autier and Gandini showed that intake of ordinary doses of vitamin D supplements appears to be associated with decreases in total mortality rates²²⁾. They have identified 18 independent randomized controlled trials, including 57,311 participants. The relative risk for mortality from any cause was 0.93 (95% CI, 0.87–0.99)²²⁾. Kandula et al. have reported on vitamin D supplementation in CKD by meta-analysis²³⁾. Among observational studies and randomized controlled trials, significant improvement was observed in serum 25(OH)D levels, along with an associated decline in PTH levels²³⁾. A low incidence of hypercalcemia and hyperphosphatemia has been reported with vitamin D supplementation. However, included studies were mostly of low to moderate quality and did not show beneficial effects on hard clinical endpoints²³⁾. Kovesdy et al. reported on the benefit of activated vitamin D treatment in patients with predialysis CKD²⁴⁾. Two hundred fifty-eight of 520 subjects received treatment with calcitriol. The incidence rate for mortality and combined death and dialysis initiation was significantly lower in treated than in untreated patients. Treatment with calcitriol was associated with a trend toward a lower incidence of dialysis. These results were consistent across different subgroups²⁴⁾.

One prospective cohort study of incident dialysis patients in the Netherlands (the NECOSAD) revealed an

Table 2. Selected Clinical Studies on Vitamin D Deficiency and Treatment in Patients with Non-Chronic Kidney Disease (CKD), Non-Dialytic CKD, and Dialytic CKD

Population	Vitamin D	Patients	Follow-up	All cause mortality	Cardiovascular mortality	Other benefits
Non CKD patients						
NHANES III ¹⁸⁾	25(OH)D < 17.8 ng/mL	13,331	20 years	1.26 (1.08–1.46)	1.20 (0.87–1.64)	
Diagnostic angiography ¹⁹⁾	25(OH)D < 7.6 ng/mL	3,258	7.7 years	2.08 (1.60–2.70)	2.22 (1.57–3.13)	
Meta-analysis (Autier et al.) ²⁰⁾	Vitamin D supplement (300–2,000 IU)	57,311	5.7 years	0.93 (0.87–0.99)	0.84 (0.65–1.10)	
Non dialytic CKD patients						
US veterans (Kovesdy et al.) ²²⁾	Calcitriol	520	2.1 years	0.35 (0.23–0.54)	–	
Meta-analysis (Kandula et al.) ²¹⁾	Vitamin D supplement (5,000–300,000 IU)	540		–	–	decline in PTH
Dialytic CKD patients						
NECOSAD ²³⁾	25(OH)D < 10 ng/mL	762	3 year	1.5 (1.0–2.1)	1.7 (1.1–2.7)	
Teng et al. ²⁴⁾	Activated vitamin D	51,037	2 year	0.8 (0.76–0.83)	7.6/100 person-year vs. 14.6/100 person-year	

NHANES III, Third National Health and Nutrition Examination Survey; NECOSAD, Netherlands Cooperative Study on the Adequacy of Dialysis; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone.

association of vitamin D deficiency in dialysis patients with an adverse health outcome, in particular, with short-term cardiovascular mortality²⁵⁾. Teng et al. reported on a historical cohort study of activated injectable vitamin D and hemodialysis survival²⁶⁾. During a 2-year observational period, 37,173 patients on hemodialysis received activated injectable vitamin D, and 13,864 did not. At 2 years, the mortality rate was 13.8/100 person-years in the group that received injectable vitamin D, compared with 28.6/100 person-years in the non-vitamin D group ($P < 0.001$). The incidence of cardiovascular-related mortality was 7.6/100 person-years in the injectable vitamin D group, compared with 14.6/100 person-years in the non-vitamin D group ($P < 0.001$). The study by Wolf et al. also showed that, although low vitamin D levels were associated with increased mortality, significant interactions were noted among vitamin D levels, subsequent active vitamin D therapy, and survival²⁷⁾. Compared with patients with the highest 25(OH)D or 1,25(OH)₂D levels who received therapy, untreated deficient patients showed a significantly increased risk for early mortality²⁷⁾ (Table 2).

Summary

In summary, vitamin D deficiency is common not

only in CKD patient but also in the general population. Reduced VDR activation occurs early in CKD. Low 25(OH)D is a risk factor for and is predictive of cardiovascular events. Decreased VDR activation is a major pathophysiological factor in the development of secondary hyperparathyroidism and also contributes to CKD morbidity and mortality. Patients with CKD have reduced VDR activation. Restoration of the physiology of VDR activation should be essential therapy for CKD patients.

References

- 1) Norman AW, Bouillon R: Vitamin D nutritional policy needs a vision for the future. *Exp Biol Med* (Maywood) 235:1034-1045, 2010
- 2) Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and vitamin D insufficiency into perspective. *Br J Nutr* 94:483-492, 2005
- 3) Choi N: Kidney and phosphate metabolism. *Electrolyte Blood Press* 6:77-85, 2008
- 4) Bergwitz C, Juppner H: Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. *Annu Rev Med* 61:91-104, 2010
- 5) Garcia-Canton C, Bosch E, Ramirez A, et al.: Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. *Nephrol Dial Transplant* 26:2250-2256, 2011
- 6) Adragao T, Pires A, Lucas C, et al.: A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients.

- Nephrol Dial Transplant 19:1480-1488, 2004
- 7) Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. *Atherosclerosis* 132:245-250, 1997
 - 8) Razzaque MS: The dualistic role of vitamin D in vascular calcifications. *Kidney Int* 79:708-714, 2011
 - 9) Maalouf NM: The noncalcitropic actions of vitamin D: recent clinical developments. *Curr Opin Nephrol Hypertens* 17:408-415, 2008
 - 10) Motiwala SR, Wang TJ: Vitamin D and cardiovascular disease. *Curr Opin Nephrol Hypertens* 20:345-353, 2011
 - 11) Henry HL, Bouillon R, Norman AW, et al.: 14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. *J Steroid Biochem Mol Biol* 121:4-6, 2010
 - 12) Forrest KY, Stuhldreher WL: Prevalence and correlates of vitamin D deficiency in US adults. *Nutr Res* 31:48-54, 2011
 - 13) Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C: Vitamin D status and health correlates among German adults. *Eur J Clin Nutr* 62:1079-1089, 2008
 - 14) Rockell JE, Skeaff CM, Williams SM, Green TJ: Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older. *Osteoporos Int* 17:1382-1389, 2006
 - 15) Choi HS, Oh HJ, Choi H, et al.: Vitamin D insufficiency in Korea—a greater threat to younger generation: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008. *J Clin Endocrinol Metab* 96:643-651, 2011
 - 16) Levin A, Bakris GL, Molitch M, et al.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int* 71:31-38, 2007
 - 17) Evenepoel P, Meijers B, Viaene L, et al.: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. *Clin J Am Soc Nephrol* 5:1268-1276, 2010
 - 18) Lee YM, Park SW, Kim JS, et al.: 25-Hydroxyvitamin D status in patients with chronic kidney disease in a single center. *Korean J Nephrol* 29:458-464, 2010
 - 19) Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int (Suppl 113):S1-130*, 2009
 - 20) Melamed ML, Michos ED, Post W, Astor B: 25-hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med* 168:1629-1637, 2008
 - 21) Dobnig H, Pilz S, Scharnagl H, et al.: Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Arch Intern Med* 168:1340-1349, 2008
 - 22) Autier P, Gandini S: Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med* 167:1730-1737, 2007
 - 23) Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD: Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Clin J Am Soc Nephrol* 6:50-62, 2011
 - 24) Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. *Arch Intern Med* 168:397-403, 2008
 - 25) Drechsler C, Verduijn M, Pilz S, et al.: Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. *Nephrol Dial Transplant* 26:1024-1032, 2011
 - 26) Teng M, Wolf M, Ofsthun MN, et al.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol* 16:1115-1125, 2005
 - 27) Wolf M, Betancourt J, Chang Y, et al.: Impact of activated vitamin D and race on survival among hemodialysis patients. *J Am Soc Nephrol* 19:1379-1388, 2008